
Sign up to save your podcasts
Or
The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health?
Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants.
Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts
Hosted on Acast. See acast.com/privacy for more information.
4.7
115115 ratings
The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health?
Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants.
Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts
Hosted on Acast. See acast.com/privacy for more information.
4,199 Listeners
917 Listeners
585 Listeners
107 Listeners
2,529 Listeners
1,070 Listeners
1,415 Listeners
101 Listeners
36 Listeners
890 Listeners
344 Listeners
496 Listeners
78 Listeners
68 Listeners
100 Listeners